Melanoma: all 3,073 studies

Page 15 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815Active, not recruitingNCT05557045Phase 1
• Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsActive, not recruitingNCT05538130Phase 1
• A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1
• Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant MelanomaActive, not recruitingNCT05520294
• Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)Active, not recruitingNCT05520099
• Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System MetastasisStatus unknownNCT05510466
• A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnNCT05496192Phase 2
• A Study of Tumor Imaging With Multispectral Optoacoustic TomographyActive, not recruitingNCT05488483
• Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2WithdrawnNCT05482074Phase 2
• Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic MelanomaActive, not recruitingNCT05470283Phase 1
• Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICGStatus unknownNCT05467137Phase 4
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT05461430
• Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced MelanomaStatus unknownNCT05451407Phase 1
• Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT)Status unknownNCT05445752
• Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point InhibitorTerminatedNCT05436990Phase 2
• A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic TherapyCompletedNCT05432622
• FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
• Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German DatabaseCompletedNCT05426239
• Effectiveness of Group and Individual Training in EFT for Patients in Remission From MelanomaCompletedNCT05421988Not applicable
• A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal MelanomaCompletedNCT05420324Phase 2
• A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic MelanomaCompletedNCT05419388Phase 2
• A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaActive, not recruitingNCT05418972Phase 2
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasActive, not recruitingNCT05415072Phase 1/2
• Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver MetastasisStatus unknownNCT05406466Phase 2
• Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsmsStatus unknownNCT05402046Not applicable
• Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 StudyTerminatedNCT05393713Phase 1
• Fast Track Diagnosis of Skin Cancer by Advanced Imaging Technologies and Tumour TapestrippingCompletedNCT05389085Not applicable
• E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic MelanomaTerminatedNCT05388877Phase 1
• Education for Prevention of Melanoma in Hispanic PopulationsTerminatedNCT05388851Phase 2
• Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic CancerCompletedNCT05380336
• A Clinical Trial of Regorafenib in Patients With Pretreated Advanced MelanomaActive, not recruitingNCT05370807Phase 2
• The Impact of a Prevention Program on Sun Risks in Primary School in Tropical French RegionCompletedNCT05367180Not applicable
• Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingNCT05358938Early Phase 1
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Active, not recruitingNCT05355701Phase 1
• A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128Active, not recruitingNCT05354102Phase 1
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaActive, not recruitingNCT05352672Phase 3
• Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1
• NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)CompletedNCT05340621Phase 1/2
• Tebentafusp in Molecular Relapsed Disease (MRD) MelanomaActive, not recruitingNCT05315258Phase 2
• A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic MelanomaActive, not recruitingNCT05309421Phase 2
• Overcoming Primary Resistance to Immunotherapy in Metastatic MelanomaCompletedNCT05304546Phase 2
• Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and MelanomaCompletedNCT05303493Phase 1
• "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"WithdrawnNCT05299580Phase 2
• A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedNCT05293496Phase 1
• CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaActive, not recruitingNCT05289193Phase 2
• Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical RespondersActive, not recruitingNCT05286294Phase 2
• Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)CompletedNCT05282901Phase 2
• Zr89 + PET Companion TrialActive, not recruitingNCT05279027Early Phase 1
• Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT MutStatus unknownNCT05274438Phase 2
• Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Active, not recruitingNCT05270044Phase 3
• Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)TerminatedNCT05266430
• Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy SensitizationSuspendedNCT05264974Phase 1
• A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05238883Phase 1
• Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid TumorsStatus unknownNCT05235607Phase 1
• A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c MelanomaTerminatedNCT05234437Phase 2
• A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.CompletedNCT05230186
• A Study of HFB301001 in Adult Patients With Advanced Solid TumorsTerminatedNCT05229601Phase 1
• Video Education With Result Dependent dIsclosureCompletedNCT05225428Not applicable
• Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruitingNCT05222932Phase 1
• HL-085 in NRAS-mutated Advanced MelanomaCompletedNCT05217303Phase 2
• A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsCompletedNCT05199584Phase 2
• A Clinical Trial of TAA06 Injection in Advanced Solid TumorsStatus unknownNCT05190185Phase 1
• Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorSActive, not recruitingNCT05180942
• Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical StudyStatus unknownNCT05180851Early Phase 1
• A Phase 1/2 Study of BA3071 in Patients With Solid TumorsActive, not recruitingNCT05180799Phase 1/2
• The Role of Genetic Mutations and of Circulating mRNAs in Uveal MelanomaStatus unknownNCT05179174
• Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsActive, not recruitingNCT05176470Phase 1
• pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicEStatus unknownNCT05171374
• Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1
• PD-L1 Targeting Nanobody Probe for PET Imaging of Solid TumorStatus unknownNCT05156515Not applicable
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)Active, not recruitingNCT05155254Phase 3
• Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid TumorsCompletedNCT05148325Phase 1
• Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma PatientsStatus unknownNCT05145829Not applicable
• Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory MelanomaActive, not recruitingNCT05130177Phase 2
• Proton Pencil Beam Scanning GRID for Treatment of Bulky TumorsActive, not recruitingNCT05121545Not applicable
• Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical PracticeStatus unknownNCT05120024
• Melanoma: Genomic Profiles, Molecular Markers and Therapeutic ImplicationsActive, not recruitingNCT05119829
• A Study of Adjuvant Melanoma Stakeholder Treatment PreferencesCompletedNCT05115006
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 MutationStatus unknownNCT05114603Phase 2
• Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05104801Phase 2
• Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg FormulationsStatus unknownNCT05103891Phase 1
• The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma PatientsCompletedNCT05102773
• Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV MelanomaStatus unknownNCT05097378Phase 2
• Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal MelanomaActive, not recruitingNCT05089370Phase 1/2
• PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic ProliferationStatus unknownNCT05089188
• Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant MelanomaStatus unknownNCT05087602Phase 2
• Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma SettingCompletedNCT05079113
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOActive, not recruitingNCT05078047Phase 3
• Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver MetastasisStatus unknownNCT05070221Phase 1
• Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver MetastasisStatus unknownNCT05068453Phase 1
• A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingNCT05068102Phase 1
• Biomarker-driven Therapy for MelanomaCompletedNCT05063058Not applicable
• Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of RecurrenceStatus unknownNCT05062096Not applicable
• This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.TerminatedNCT05061940
• A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursActive, not recruitingNCT05057013Phase 1/2
• Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma PatientsCompletedNCT05054062Not applicable
• A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With CancerActive, not recruitingNCT05053230Not applicable
• To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced MelanomaStatus unknownNCT05051865Phase 2

← Melanoma overview